Delirium is a syndrome of neuropsychiatric signs and symptoms that can accompany virtually any serious medical condition. Delirium is characterized by a disturbance of attention and awareness, as well as variety of other aspects of cognition that develops over a short period of time in response to another medical condition. It is an independent risk factor for increased morbidity and mortality and is associated with increased lengths of stay and costs of care. Despite this, it frequently goes unrecognized, and debate continues about the best prevention and treatment strategies. This article will review the current best practices for the prevention and treatment of delirium and how collaborative care can aid in improving outcomes and minimizing adverse events for patients suffering from delirium.
KishiYKatoMOkuyamaT. Delirium: patient characteristics that predict a missed diagnosis at psychiatric consultation. Gen Hosp Psychiatry2007; 29: 442–445.
2.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
3.
FongTGTulebaevSRInouyeSK. Delirium in elderly adults: diagnosis, prevention, and treatment. Nat Rev Neurol2009; 5: 210–220.
4.
InouyeSKForemanMDMionLC. Nurses’ recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Arch Intern Med2001; 161: 2467–2473.
5.
ZhangZPanLNiH. Impact of delirium on clinical outcome in critically ill patients: a meta-analysis. Gen Hosp Psychiatry2013; 35: 105–111.
6.
MilbrandtEBDeppenSHarrisonPL. Costs associated with delirium in mechanically ventilated patients. Crit Care Med2004; 32: 955–962.
7.
WitloxJEurelingsLSde JongheJF. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA2010; 304: 443–451.
8.
InouyeSKBogardusSTJrCharpentierPA. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med1999; 340: 669–676.
O’MahonyRMurthyLAkunneA. Guideline development group. Synopsis of the national institute for health and clinical excellence guideline for prevention of delirium. Ann Intern Med2011; 154: 746–751.
GilmoreMLWolfeDJ. Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence—but not duration—in high-incidence samples: a meta-analysis. Gen Hosp Psychiatry2013; 35: 370–375.
13.
GamberiniMBolligerDLurati BuseGA. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery—a randomized controlled trial. Crit Care Med2009; 37: 1762–1768.
14.
FordAHAlmeidaOP. Pharmacological interventions for preventing delirium in the elderly. Maturitas2015; 81: 287–292.
15.
BellapartJBootsR. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth2012; 108: 572–580.
16.
Al-AamaTBrymerCGutmanisI. Melatonin decreases delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry2011; 26: 687–694.
17.
HattaKKishiYWadaK. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry2014; 71: 397–403.
18.
NelsonSMuzykAJBucklinMH. Defining the role of dexmedetomidine in the prevention of delirium in the intensive care unit. Biomed Res Int2015; 2015: 635737.
19.
MaclullichAMFergusonKJMillerT. Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res2008; 65: 229–238.
20.
MorandiAHughesCGThompsonJL. Statins and delirium during critical illness: a multicenter, prospective cohort study. Crit Care Med2014; 42: 1899–1909.
21.
InouyeSKWestendorpRGSaczynskiJS. Delirium in elderly people. Lancet2014; 383: 911–922.
22.
InouyeSKvan DyckCHAlessiCA. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med1990; 113: 941–948.
23.
ElyEWMargolinRFrancisJ. Evaluation of delirium in critically ill patients: validation of the confusion assessment method for the intensive care unit (CAM-ICU). Crit Care Med2001; 29: 1370–1379.
24.
TesarGEMurrayGBCassemNH. Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients. J Clin Psychopharmacol1985; 5: 344–347.
25.
Kishi T, Hirota T, Matsunaga S, et al. Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomized controlled trials. J Neurol Neurosurg Psychiatry. Epub ahead of print 4 September 2015. DOI: 10.1136/jnnp-2015-311049.
26.
WangHRWooYSBahkWM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci2013; 67: 323–331.
27.
FriedmanJISoleimaniLMcGonigleDP. Pharmacological treatments of non-substance-withdrawal delirium: a systematic review of prospective trials. Am J Psychiatry2014; 171: 151–159.
28.
LeuchtSCiprianiASpineliL. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet2013; 382: 951–962.
29.
ReadeMCO’SullivanKBatesS. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomized open-label trial. Crit Care2009; 13: R75.
30.
PasinLGrecoTFeltraccoP. Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials. PLoS One2013; 8: e82913.
31.
Mayo-SmithMF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American society of addiction medicine working group on pharmacological management of alcohol withdrawal. JAMA1997; 278: 144–151.
